{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:14:11Z","timestamp":1779290051389,"version":"3.51.4"},"reference-count":18,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,12,9]],"date-time":"2005-12-09T00:00:00Z","timestamp":1134086400000},"content-version":"vor","delay-in-days":6155,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[1989,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Two hundred thirty\u2010eight patients with psoriatic arthritis were entered into a 6\u2010month, multicenter, double\u2010blind trial comparing auranofin and placebo. Polyarthritis (&gt;5 tender joints) was present in 90% of the patients, and 94% were seronegative. Auranofin treatment was statistically superior to placebo treatment, according to physician's global assessment and functional scores. A trend in favor of auranofin treatment was seen for each of the other disease parameters studied. Psoriasis worsened in 6 auranofin\u2010treated patients and in 3 placebo\u2010treated patients. The incidence and nature of other side effects were similar to those observed in similar trials of patients with rheumatoid arthritis. Our observations suggest that the use of auranofin in the treatment of psoriatic arthritis is safe, although its therapeutic advantage over treatment with nonsteroidal antiinflammatory drugs alone is modest.<\/jats:p>","DOI":"10.1002\/anr.1780320208","type":"journal-article","created":{"date-parts":[[2007,2,14]],"date-time":"2007-02-14T22:40:01Z","timestamp":1171492801000},"page":"158-165","source":"Crossref","is-referenced-by-count":43,"title":["A double\u2010blind placebo\u2010controlled study of auranofin in patients with psoriatic arthritis"],"prefix":"10.1002","volume":"32","author":[{"given":"Simon","family":"Carette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei","family":"Calin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim P.","family":"McCafferty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce A.","family":"Wallin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,12,14]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(79)80001-3"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1964.01600020079020"},{"key":"e_1_2_1_4_2","first-page":"462","article-title":"Hydroxychloroquine in psoriatic arthropathy: exacerbations of psoriatic skin lesions","volume":"9","author":"Luzar MJ","year":"1982","journal-title":"J Rheumatol"},{"key":"e_1_2_1_5_2","first-page":"833","article-title":"Antimalarials in psoriatic arthritis (letter)","volume":"10","author":"Trnavsk\u00fd K","year":"1983","journal-title":"J Rheumatol"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780210504"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.39.3.279"},{"key":"e_1_2_1_8_2","first-page":"3739","article-title":"Retrospective observations on the progress, therapy and prognosis of psoriatic arthritis","volume":"35","author":"Wirth W","year":"1985","journal-title":"Therapeiwoche"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1964.03070100037007"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270403"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780261102"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90484-9"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90539-5"},{"key":"e_1_2_1_14_2","first-page":"695","article-title":"An analysis of worldwide safety experience with auranofin","volume":"12","author":"Heuer MA","year":"1985","journal-title":"J Rheumatol"},{"key":"e_1_2_1_15_2","volume-title":"Psoriatic arthritis, Textbook of Rheumatology","author":"Wright V","year":"1985"},{"key":"e_1_2_1_16_2","first-page":"34","article-title":"Clinical aspects of psoriatic arthritis","volume":"8","author":"Vasey FB","year":"1982","journal-title":"Compr Ther"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.27.1.64"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780160202"},{"key":"e_1_2_1_19_2","first-page":"116","article-title":"A double\u2010blind controlled evaluation of azathioprine treatment in rheumatoid arthritis and psoriatic arthritis (abstract)","volume":"15","author":"Levy J","year":"1972","journal-title":"Arthritis Rheum"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fanr.1780320208","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/anr.1780320208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T20:27:01Z","timestamp":1700684821000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/anr.1780320208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1989,2]]}},"alternative-id":["10.1002\/anr.1780320208"],"URL":"https:\/\/doi.org\/10.1002\/anr.1780320208","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989,2]]}}}